切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2024, Vol. 18 ›› Issue (01) : 76 -80. doi: 10.3877/cma.j.issn.1674-0793.2024.01.015

综述

胆管癌的光动力治疗
高彬, 阿曼塔依·努尔塔依, 宁江红, 邵英梅()   
  1. 830054 乌鲁木齐,新疆医科大学第一附属医院消化血管外科中心肝胆包虫病外科
  • 收稿日期:2023-08-03 出版日期:2024-02-01
  • 通信作者: 邵英梅
  • 基金资助:
    省部共建中亚高发病成因与防治国家重点实验室开放课题(SKL-HIDCA-2020-BC); 省部共建中亚高发病成因与防治国家重点实验室开放课题(SKL-HIDCA-2021-12); 新疆维吾尔自治区高校科研计划项目(XJEDU2021I016)

Photodynamic therapy of cholangiocarcinoma

Bin Gao, Nuertayi Amantayi·, Jianghong Ning, Yingmei Shao()   

  1. Department of Hepatobiliary Hydatid Diseases, Digestive and Vascular Surgery Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
  • Received:2023-08-03 Published:2024-02-01
  • Corresponding author: Yingmei Shao
引用本文:

高彬, 阿曼塔依·努尔塔依, 宁江红, 邵英梅. 胆管癌的光动力治疗[J/OL]. 中华普通外科学文献(电子版), 2024, 18(01): 76-80.

Bin Gao, Nuertayi Amantayi·, Jianghong Ning, Yingmei Shao. Photodynamic therapy of cholangiocarcinoma[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(01): 76-80.

胆管癌发病隐匿且恶性程度较高,通常在发现时已达疾病晚期,已丧失根治性手术切除机会。对于晚期胆管癌的姑息性治疗,传统手段常包括胆道支架置入、射频消融术、放化疗等,但胆管癌对放化疗并不敏感。近年来,光动力疗法(PDT)成为了晚期胆管癌患者的另一项选择,作为一种创伤小、不良反应少的治疗方式,逐步应用于晚期胆管癌的姑息性治疗且已取得良好的疗效,引起了学术界的广泛关注。本文从PDT的原理、在胆管癌中的应用及优缺点等方面进行综述。

Changiocarcinoma, insidious and highly malignant, is usually at the advanced stage when it is found out, and patients have lost the chance of radical surgical resection. For the palliative treatment of advanced cholangiocarcinoma, traditional methods include biliary stent placement, radiofrequency ablation, chemoradiotherapy and so on, but cholangiocarcinoma is not sensitive to chemoradiotherapy. In recent years, photodynamic therapy (PDT) has become another option for patients with advanced cholangiocarcinoma due to less trauma and adverse effects. It has been gradually applied to the palliative treatment of advanced cholangiocarcinoma and has achieved good results, thus attracts wide attention in the academic community. This paper summarizes the principles, advantages and disadvantages of the application of PDT for changiocarcinoma.

[1]
Valery PC, Laversanne M, Clark PJ, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide[J]. Hepatology, 2018, 67(2): 600-611.
[2]
Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis[J]. Am J Gastroenterol, 2000, 95(1): 204-207.
[3]
Höblinger A, Gerhardt T, Gonzalez-Carmona MA, et al. Feasibility and safety of long-term photodynamic therapy (PDT) in the palliative treatment of patients with hilar cholangiocarcinoma[J]. Eur J Med Res, 2011, 16(9): 391-395.
[4]
Lu Y, Liu L, Wu JC, et al. Efficacy and safety of photodynamic therapy for unresectable cholangiocarcinoma: A meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2015, 39(6): 718-724.
[5]
Donohoe C, Senge MO, Arnaut LG, et al. Cell death in photodynamic therapy: from oxidative stress to anti-tumor immunity[J]. Biochim Biophys Acta Rev Cancer, 2019, 1872(2): 188308.
[6]
袁耒, 邹志强, 李传海, 等. 早期食管癌的光动力治疗[J/CD]. 中华消化病与影像杂志(电子版), 2022, 12(5): 306-309.
[7]
Dichiara M, Prezzavento O, Marrazzo A, et al. Recent advances in drug discovery of phototherapeutic non-porphyrinic anticancer agents[J]. Eur J Med Chem, 2017, 142: 459-485.
[8]
Obaid G, Broekgaarden M, Bulin AL, et al. Photonanomedicine: A convergence of photodynamic therapy and nanotechnology[J]. Nanoscale, 2016, 8(25): 12471-12503.
[9]
Li Z, Jiang X, Xiao H, et al. Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma[J]. Surg Endosc, 2021, 35(10): 5655-5664.
[10]
Brunaldi VO, Brunaldi JE, Vollet-Filho JD, et al. Photodynamic therapy of extrahepatic cholangiocarcinoma using digital cholangioscopy[J]. Arq Bras Cir Dig, 2020, 33(1): e1490.
[11]
Talreja JP, DeGaetani M, Sauer BG, et al. Photodynamic therapy for unresectable cholangiocarcinoma: contribution of single operator cholangioscopy for targeted treatment[J]. Photochem Photobiol Sci, 2011, 10(7): 1233-1238.
[12]
Choi HJ, Moon JH, Ko BM, et al. Clinical feasibility of direct peroral cholangioscopy-guided photodynamic therapy for inoperable cholangiocarcinoma performed by using an ultra-slim upper endoscope (with videos)[J]. Gastrointest Endosc, 2011, 73(4): 808-813.
[13]
Zhou J, Xiong L, Liu W, et al. SpyGlass-guided photodynamic therapy for unresectable cholangiocarcinoma: A case report and review of the literature[J]. Front Oncol, 2022, 12: 890735.
[14]
Choi JH, Oh D, Lee JH, et al. Initial human experience of endoscopic ultrasound-guided photodynamic therapy with a novel photosensitizer and a flexible laser-light catheter[J]. Endoscopy, 2015, 47(11): 1035-1038.
[15]
宋铭杰, 韩青雷, 李佳隆, 等. 内镜下晚期肝外胆管恶性肿瘤消融治疗研究现况[J/CD]. 中华普外科手术学杂志(电子版), 2023, 17(3): 340-342.
[16]
Pereira SP, Jitlal M, Duggan M, et al. PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer[J]. ESMO Open, 2018, 3(5): e000379.
[17]
许博, 席大勇, 蒲唯高, 等. 双金属支架联合光动力治疗及靶向、免疫治疗在远端胆管癌中的应用[J]. 肝胆胰外科杂志, 2021, 33(7): 427-433.
[18]
Moole H, Tathireddy H, Dharmapuri S, et al. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: A systematic review and meta-analysis[J]. World J Gastroenterol, 2017, 23(7): 1278-1288.
[19]
Mohan BP, Chandan S, Khan SR, et al. Photodynamic therapy (PDT), radiofrequency Ablation (RFA) with biliary stents in palliative treatment of unresectable extrahepatic cholangiocarcinoma: A systematic review and meta-analysis[J]. J Clin Gastroenterol, 2022, 56(2): e153-e160.
[20]
Song S, Gong S, Lei T, et al. Comparative efficacy and safety of local palliative therapeutics for unresectable malignant biliary obstruction: A Bayesian network meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2022, 16(6): 555-567.
[21]
Schmidt A, Bloechinger M, Weber A, et al. Short-term effects and adverse events of endoscopically applied radiofrequency ablation appear to be comparable with photodynamic therapy in hilar cholangiocarcinoma[J]. United European Gastroenterol J, 2016, 4(4): 570-579.
[22]
Beltrán Hernández I, Yu Y, Ossendorp F, et al. Preclinical and clinical evidence of immune responses triggered in oncologic photodynamic therapy: clinical recommendations[J]. J Clin Med, 2020, 9(2): 333.
[23]
Yu Y, Wang N, Wang Y, et al. Photodynamic therapy combined with systemic chemotherapy for unresectable extrahepatic cholangiocarcinoma: A systematic review and meta-analysis[J]. Photodiagnosis Photodyn Ther, 2023, 41: 103318.
[24]
Wentrup R, Winkelmann N, Mitroshkin A, et al. Photodynamic therapy plus chemotherapy compared with photodynamic therapy alone in hilar nonresectable cholangiocarcinoma[J]. Gut Liver, 2016, 10(3): 470-475.
[25]
Gonzalez-Carmona MA, Bolch M, Jansen C, et al. Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma[J]. Aliment Pharmacol Ther, 2019, 49(4): 437-447.
[26]
卢学敏, 刘黎, 许泓, 等. 光化学内化作用及其在基因输送中的应用[J]. 上海交通大学学报(医学版), 2018, 38(3): 353-356.
[27]
Trojan J, Hoffmeister A, Neu B, et al. Photochemical internalization of gemcitabine is safe and effective in locally advanced inoperable cholangiocarcinoma[J]. Oncologist, 2022, 27(6): e430-e433.
[28]
Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: A phase Ⅱ pilot study[J]. Cancer, 2003, 97(11): 2783-2790.
[29]
Wagner A, Wiedmann M, Tannapfel A, et al. Neoadjuvant down-sizing of hilar cholangiocarcinoma with photodynamic therapy--long-term outcome of a phase Ⅱ pilot study[J]. Int J Mol Sci, 2015, 16(11): 26619-26628.
[30]
Grendar J, Grendarova P, Sinha R, et al. Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: A systematic review[J]. HPB (Oxford), 2014, 16(4): 297-303.
[31]
Sapisochin G, de Lope CR, Gastaca M, et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: A Spanish matched cohort multicenter study[J]. Ann Surg, 2014, 259(5): 944-952.
[32]
Vilchez V, Shah MB, Daily MF, et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: An analysis of the UNOS database[J]. HPB (Oxford), 2016, 18(1): 29-34.
[33]
Cosgrove ND, Al-Osaimi AM, Sanoff HK, et al. Photodynamic therapy provides local control of cholangiocarcinoma in patients awaiting liver transplantation[J]. Am J Transplant, 2014, 14(2): 466-471.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[3] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[4] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[5] 薛庆, 施赛叶, 徐雅文, 盛夏, 张芹芹. 追踪方法学联合失效模式与效应分析在膀胱灌注化疗患者中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 553-559.
[6] 郭兵, 王万里, 何凯, 黄汉生. 腹腔镜下肝门部胆管癌根治术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 143-143.
[7] 魏丽霞, 张安澜, 周宝勇, 李明. 腹腔镜下Ⅲb型肝门部胆管癌根治术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 145-145.
[8] 马振威, 宋润夫, 王兵. ERCP胆道内支架与骑跨十二指肠乳头支架置入治疗不可切除肝门部胆管癌疗效的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 807-812.
[9] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[10] 林科灿, 罗柳平. 肝胰十二指肠切除术在胆囊癌和胆管癌应用中的关键问题[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 774-778.
[11] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[12] 石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[13] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[14] 张颖, 赵鑫, 陈佳梅, 李雁. 术前化疗对CRS+HIPEC 治疗腹膜假黏液瘤预后影响的meta 分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 826-835.
[15] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?